Key Financial Data Of Reporting Company

OncoTherapy Science, Inc. - Filing #7300533

Concept As at
2024-09-30
2024-04-01 to
2024-09-30
2023-04-01 to
2024-03-31
As at
2024-03-31
As at
2023-09-30
2023-04-01 to
2023-09-30
Key financial data of reporting company
Business results of reporting company
Ordinary profit (loss)
-545,169,000 JPY
-1,136,373,000 JPY
-708,185,000 JPY
Net assets
1,000,348,000 JPY
353,666,000 JPY
934,995,000 JPY
Total assets
1,548,092,000 JPY
867,275,000 JPY
1,167,733,000 JPY
Basic earnings (loss) per share
-2.18
-6.05
-3.42
Diluted earnings per share
Equity-to-asset ratio
0.599 xbrli:pure
0.322 xbrli:pure
0.734 xbrli:pure
Net cash provided by (used in) operating activities
-578,766,000 JPY
-1,227,990,000 JPY
-879,851,000 JPY
Net cash provided by (used in) investing activities
JPY
-33,354,000 JPY
-33,570,000 JPY
Net cash provided by (used in) financing activities
1,149,384,000 JPY
671,365,000 JPY
677,229,000 JPY
Cash and cash equivalents
1,098,274,000 JPY
527,656,000 JPY
881,443,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.